Company Overview and News
PETALING JAYA: With the Government expected to make announcements on changes to toll charges on expressways, attention will be focused on the impact this may have on concessionaires and the national finances.
KUALA LUMPUR: Vertice Bhd , Lee Swee Kiat Group Bhd and Bina Puri Holdings Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
PETALING JAYA: Property and construction outfit Bina Puri Holdings Bhd has inked a deal with Warisan Harta Sabah Sdn Bhd to develop two small hydropower sites in Kota Belud, Sabah.
KUALA LUMPUR: Scientex Bhd , Advancecon Holdings Bhd, Bina Puri Holdings Bhd , Titijaya Land Bhd and Muhibbah Engineering (M) Bhd are among the stocks to watch on Friday, according to JF Apex Research.
PETALING JAYA: Bina Puri Holdings Bhd and Titijaya Land Bhd are entering into a new joint venture (JV) to develop a mixed residential and commercial project on 11.2 acres of land in Brickfields, Kuala Lumpur.
PETALING JAYA: Construction outfit Pintaras Jaya Bhd has been awarded a contract worth RM68.5mil by Bina Puri Holdings Bhd to undertake piling and substructure works for a project located in Brickfields, Kuala Lumpur.
KUALA LUMPUR: JF Apex Research expects Econpile Holdings Bhd , Hai-O Enterprise Bhd , United Malacca Bhd , Bina Puri Holdings Bhd and Chin Hin Group Bhd to generate trading interest today following their latest news.
Direct negotiation: The PDP for the MRT1 and MRT2 projects, MMC-Gamuda, was appointed via direct negotiation.
Group executive director Kho Pok Tong(filepic) said KKB was pursuing the supply of steel water pipes, guard rails and low/high tension steel poles required for the construction and upgrading of the over 700km Sabah portion of the highway
MarketWatch: US stocks fell on Wednesday as energy sector shares dropped for a fourth straight session, tracking crude prices, while a late run-up was thwarted by concerns over the passage of a tax revamp after Republican senators were critical of the proposal. The DJIA fell 138.19 points, or 0.59%, to close at 23,271.28, the S&P 500 .SPX ended down 0.55% at 2,564.62 and the Nasdaq dropped 31.66 points, or 0.
PETALING JAYA: Bina Puri Holdings Bhd has secured a RM35.5mil contract to undertake the pavement works and temporary road diversion from Aktif Unggul Sdn Bhd,
PT Megapower Makmur listed 245 million shares (30 per cent) under the code MPOW, with an opening price of Rp 340 (RM 0.11), up 70 per cent from the offering price of Rp 200 per share. ― Reuters picJAKARTA, July 6 — Bina Puri Holdings Bhd has achieved its latest milestone, when its subsidiary, an Independent electricity producer PT Megapower Makmur (MPOW) made its debut on the Indonesia Stock Exchange (IDX) yesterday, making the First Non-Government Link Company (Malaysia, GLC) to successfully listed on the Indonesia Stock Exchange (IDX), Bursa Efek Indonesia.
MarketWatch: A steep drop in oil prices dragged energy shares lower and kept the Dow and S&P 500 in check on Wednesday, while the Nasdaq was buoyed by gains in tech stocks. The DJIA fell 1.1 points, or 0.01%, to close at 21,478.17, the S&P 500 gained 3.53 points, or 0.15%, to 2,432.54 and the Nasdaq added 40.80 points, or 0.67%, to 6,150.86. - Reuters
Officials from Bina Puri Holdings Bhd and PT Megapower Makmur Tbk, during the latter's listing on the Indonesia Stock Exchange on July 5.
MarketWatch: The large-cap technology sector is expected to see a bump in its growth weighting when index provider FTSE Russell completes the annual refresh of its benchmarks next Friday, a move that could lift tech shares targeted in the rejig. The increased significance of tech comes on the heels of an around 20% gain in the sector this year which led to a pullback over the last week. - Reuters
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...